Системная терапия анапластического рака щитовидной железы: обзор литературы

Системная терапия анапластического рака щитовидной железы: обзор литературы

Автор: Джелялов Э.С., Слепцов И.В., Черников Р.А., Тимофеева Н.И., Белоусов А.М.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 6 т.23, 2024 года.

Бесплатный доступ

Актуальность. Анапластический рак щитовидной железы - редкое, но агрессивное заболевание с крайне низкой выживаемостью. Совершенствование диагностических и терапевтических возможностей позволило разработать комплексный подход (хирургия + лучевая терапия + возможности системной противоопухолевой терапии), который способствовал улучшению общей выживаемости, что подчеркивает важность участия мультидисциплинарной команды. Однако, несмотря на широкое применение химиотерапии, таргетной терапии и иммунотерапии, результаты лечения пациентов остаются неутешительными. Цель исследования - проанализировать литературу о подходах к системной терапии анапластического рака щитовидной железы, выделить ключевые недостатки существующих методов лечения и определить перспективные направления исследований в данной области. Материал и методы. Поиск литературы для подготовки обзора осуществлен по базам данных Web of Science, Scopus, MedLine, The Cochrane Library, РИНЦ. В ходе поиска проанализировано 395 источников, из них отобрано 59 научных публикаций. В обзор включены исследования за период с 1985 по 2024 г.

Еще

Анапластический рак щитовидной железы, химиотерапия, иммунотерапия, таргетная терапия, обзор литературы

Короткий адрес: https://sciup.org/140308744

IDR: 140308744   |   DOI: 10.21294/1814-4861-2024-23-6-138-148

Список литературы Системная терапия анапластического рака щитовидной железы: обзор литературы

  • Jannin A., Escande A., Al Ghuzlan A., Blanchard P., Hartl D., Chevalier B., Deschamps F., Lamartina L., Lacroix L., Dupuy C., Baudin E., Do Cao C., Hadoux J. Anaplastic Thyroid Carcinoma: An Update. Cancers (Basel). 2022; 14(4): 1061. https://doi.org/10.3390/cancers14041061.
  • Bible K.C., Kebebew E., Brierley J., Brito J.P., Cabanillas M.E., Clark T.J. Jr., Di Cristofano A., Foote R., Giordano T., Kasperbauer J., Newbold K., Nikiforov Y.E., Randolph G., Rosenthal M.S., Sawka A.M., Shah M., Shaha A., Smallridge R., Wong-Clark C.K. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021; 31(3): 337-86. https://doi.org/10.1089/thy.2020.0944. Erratum in: Thyroid. 2021; 31(10): 1606-7. https://doi.org/10.1089/thy.2020.0944.correx.
  • Smallridge R.C., Copland J.A. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010; 22(6): 486-97. https://doi.org/10.1016/j.clon.2010.03.013.
  • Kebebew E., Greenspan F.S., Clark O.H., Woeber K.A., McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005; 103(7): 1330-5. https://doi.org/10.1002/cncr.20936.
  • Nagaiah G., Hossain A., Mooney C.J., Parmentier J., Remick S.C. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011. https://doi.org/10.1155/2011/542358.
  • Passler C., Scheuba C., Prager G., Kaserer K., Flores J.A., Vierhapper H., Niederle B. Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg. 1999; 384(3): 284-93. https://doi.org/10.1007/s004230050205.
  • Dijkstra B., Prichard R.S., Lee A., Kelly L.M., Smyth P.P., Crotty T., McDermott E.W., Hill A.D., O'Higgins N. Changing patterns of thyroid carcinoma. Ir J Med Sci. 2007; 176(2): 87-90. https://doi.org/10.1007/s11845-007-0041-y.
  • Zivaljevic V., Slijepcevic N., Paunovic I., Diklic A., Kalezic N., Marinkovic J., Zivic R., Vekic B., Sipetic S. Risk factors for anaplastic thyroid cancer. Int J Endocrinol. 2014. https://doi.org/10.1155/2014/815070.
  • Zivaljevic V.R., Vlajinac H.D., Marinkovic J.M., Kalezic N.K., Paunovic I.R., Diklic A.D. Case-control study of anaplastic thyroid cancer: goiter patients as controls. Eur J Cancer Prev. 2008; 17(2): 111-5. https://doi.org/10.1097/CEJ.0b013e3281108036.
  • Schmid D., Ricci C., Behrens G., Leitzmann M.F. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes Rev. 2015; 16(12): 1042-54. https://doi.org/10.1111/obr.12321.
  • Ma J., Huang M., Wang L., Ye W., Tong Y., Wang H. Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies. Med Sci Monit. 2015; 21: 283-91. https://doi.org/10.12659/MSM.892035.
  • Kitahara C.M., McCullough M.L., Franceschi S., Rinaldi S., Wolk A., Neta G., Olov Adami H., Anderson K., Andreotti G., Beane Freeman L.E., Bernstein L., Buring J.E., Clavel-Chapelon F., De Roo L.A., Gao Y.T., Gaziano J.M., Giles G.G., Håkansson N., Horn-Ross P.L., Kirsh V.A., Linet M.S., MacInnis R.J., Orsini N., Park Y., Patel A.V., Purdue M.P., Riboli E., Robien K., Rohan T., Sandler D.P., Schairer C., Schneider A.B., Sesso H.D., Shu X.O., Singh P.N., van den Brandt P.A., Ward E., Weiderpass E., White E., Xiang Y.B., Zeleniuch-Jacquotte A., Zheng W., Hartge P., Berrington de Gonzalez A. Anthropometric Factors and Thyroid Cancer Risk by Histological Subtype: Pooled Analysis of 22 Prospective Studies. Thyroid. 2016; 26(2): 306-18. https://doi.org/10.1089/thy.2015.0319.
  • Xu B., Fuchs T., Dogan S., Landa I., Katabi N., Fagin J.A., Tuttle R.M., Sherman E., Gill A.J., Ghossein R. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid. 2020; 30(10): 1505-17. https://doi.org/10.1089/thy.2020.0086.
  • Schürch C.M., Roelli M.A., Forster S., Wasmer M.H., Brühl F., Maire R.S., Di Pancrazi O. S., Ruepp M.D., Giger R., Perren A., Schmitt A.M., Krebs P., Charles R.P., Dettmer M.S. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. Thyroid. 2019; 29(7): 979-92. https://doi.org/10.1089/thy.2018.0555.
  • Adam P., Kircher S., Sbiera I., Koehler VF, Berg E., Knosel T., Sandner B., Fenske W.K., Blaker H., Smaxwil C., Zielke A., Sipos B., Allelein S., Schott M., Dierks C., Spitzweg C., Fassnacht M., Kroiss M. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. Front Endocrinol (Lausanne). 2021; 12. https://doi.org/10.3389/fendo.2021.712107.
  • Chintakuntlawar A.V., Rumilla K.M., Smith C.Y., Jenkins S.M., Foote R.L., Kasperbauer J.L., Morris J.C., Ryder M., Alsidawi S., Hilger C., Bible K.C. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. J Clin Endocrinol Metab. 2017; 102(6): 1943-50. https://doi.org/10.1210/jc.2016-3756.
  • Wong K.S., Lorch J.H., Alexander E.K., Nehs M.A., Nowak J.A., Hornick J.L., Barletta J.A. Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas. Thyroid. 2019; 29(5): 666-73. https://doi.org/10.1089/thy.2018.0716.
  • Rocha M.L., Schmid K.W., Czapiewski P. The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma - systematic review and discussion of current therapeutic options. Contemp Oncol (Pozn). 2021; 25(3): 213-23. https://doi.org/10.5114/wo.2021.110052.
  • Shimaoka K., Schoenfeld D.A., DeWys W.D., Creech R.H., DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985; 56(9): 2155-60. https://doi.org/10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903-3.0.co;2-e.
  • Tuttle R.M., Sherman E.J. Anaplastic thyroid cancer [Internet]. UpToDate. 2024. [cited 2024 Jul 1]. URL: https://www.uptodate.com/contents/anaplastic-thyroid-cancer.
  • FDA approves larotrectinib for solid tumors with NTRK gene fusions [Internet]. Food and Drug Administration (FDA). 2018. [cited 2024 Jul 5]. URL: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions.
  • First ‘histology-independent' treatment for solid tumours with a specific gene mutation [Internet]. The European Medicines Agency (EMA). 2019. [cited 2024 Jul 5]. URL: https://www.ema.europa.eu/en/news/first-histology-independent-treatment-solid-tumours-specific-gene-mutation.
  • Pierotti M.A., Bongarzone I., Borello M.G., Greco A., Pilotti S., Sozzi G. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer. 1996; 16(1): 1-14. https://doi.org/10.1002/(SICI)1098-2264(199605)16:1<1::AID-GCC1-3.0.CO;2-4.
  • Cocco E., Scaltriti M., Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018; 15(12): 731-47. https://doi.org/10.1038/s41571-018-0113-0.
  • Waguespack S.G., Drilon A., Lin J.J., Brose M.S., McDermott R., Almubarak M., Bauman J., Casanova M., Krishnamurthy A., Kummar S., Leyvraz S., Oh D.Y., Park K., Sohal D., Sherman E., Norenberg R., Silvertown J.D., Brega N., Hong D.S., Cabanillas M.E. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022; 186(6): 631-43. https://doi.org/10.1530/EJE-21-1259.
  • Doebele R.C., Drilon A., Paz-Ares L., Siena S., Shaw A.T., Farago A.F., Blakely C.M., Seto T., Cho B.C., Tosi D., Besse B., Chawla S.P., Bazhenova L., Krauss J.C., Chae Y.K., Barve M., Garrido-Laguna I., Liu S.V., Conkling P., John T., Fakih M., Sigal D., Loong H.H., Buchschacher G.L. Jr, Garrido P., Nieva J., Steuer C., Overbeck T.R., Bowles D.W., Fox E., Riehl T., Chow-Maneval E., Simmons B., Cui N., Johnson A., Eng S., Wilson T.R., Demetri G.D.; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020; 21(2): 271-82. https://doi.org/10.1016/S1470-2045(19)30691-6. Erratum in: Lancet Oncol. 2020; 21(2). https://doi.org/10.1016/S1470-2045(20)30029-2. Erratum in: Lancet Oncol. 2020; 21(7). https://doi.org/10.1016/S1470-2045(20)30345-4. Erratum in: Lancet Oncol. 2020; 21(8). https://doi.org/10.1016/S1470-2045(20)30382-X. Erratum in: Lancet Oncol. 2021; 22(10). https://doi.org/10.1016/S1470-2045(21)00538-6.
  • Wirth L.J., Sherman E., Robinson B., Solomon B., Kang H., Lorch J.,Worden F., Brose M., Patel J., Leboulleux S., Godbert Y., Barlesi F., Morris J.C., Owonikoko T.K., Tan D.S.W., Gautschi O., Weiss J., de la Fouchardiere C., BurkardM.E., Laskin J., TaylorM.H., KroissM., Medioni J., Goldman J.W., Bauer T.M., Levy B., Zhu V.W., Lakhani N., Moreno V., Ebata K., Nguyen M., Heirich D., Zhu E.Y., Huang X., Yang L., Kherani J., Rothenberg S.M., Drilon A., Subbiah V., Shah M.H., Cabanillas M.E. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020; 383(9): 825-35. https://doi.org/10.1056/NEJMoa2005651.
  • Hadoux J., Elisei R., Brose M.S., Hoff A.O., Robinson B.G., Gao M., Jarzab B., IsaevP., Kopeckova K., Wadsley J., Fuhrer D., Keam B., Bardet S., Sherman E.J., Tahara M., Hu M.I., Singh R., Lin Y., Soldatenkova V., Wright J., Lin B., Maeda P., Capdevila J., Wirth L.J.; LIBRETTO-531 Trial Investigators. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023; 389(20): 1851-61. https://doi.org/10.1056/NEJMoa2309719.
  • Subbiah V., Hu M.I., Mansfield A.S., Taylor M.H., Schuler M., Zhu V.W., Hadoux J., Curigliano G., Wirth L., Gainor J.F., Alonso G., Adkins D., Godbert Y., Ahn M.J., Cassier P.A., Cho B.C., Lin C.C., ZalutskayaA., Barata T., TraskP, ScaloriA., Bordogna W., Heinzmann S., Brose M.S. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024; 34(1): 26-40. https://doi.org/10.1089/thy.2023.0363. Erratum in: Thyroid. 2024. https://doi.org/10.1089/thy.2023.0363.correx.
  • Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3): 676-90. https://doi.org/10.1016/j.cell.2014.09.050.
  • Liu Z., Hou P., Ji M., Guan H., Studeman K., Jensen K., Vasko V., El-NaggarA.K., XingM. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008; 93(8): 3106-16. https://doi.org/10.1210/jc.2008-0273.
  • Landa I., Ibrahimpasic T., Boucai L., Sinha R., Knauf J.A., Shah R.H., Dogan S., Ricarte-Filho J.C., Krishnamoorthy G.P., Xu B., Schultz N., Berger M.F., Sander C., Taylor B.S., Ghossein R., Ganly I., Fagin J.A. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126(3): 1052-66. https://doi.org/10.1172/JCI85271.
  • Hyman D.M., Puzanov I., Subbiah V., Faris J.E., Chau I., Blay J.Y., Wolf J., Raje N.S., Diamond E.L., Hollebecque A., Gervais R., Elez-Fernandez M.E., Italiano A., Hofheinz R.D., Hidalgo M., Chan E., Schuler M., Lasserre S.F., Makrutzki M., Sirzen F., Veronese M.L., Tabernero J., Baselga J. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015; 373(8): 726-36. https://doi.org/10.1056/NEJMoa1502309. Erratum in: N Engl J Med. 2018; 379(16): 1585.
  • Subbiah V., Kreitman R.J., Wainberg Z.A., Cho J.Y., Schellens J.H.M., Soria J.C., Wen P.Y., Zielinski C., Cabanillas M.E., Urbanowitz G., Mookerjee B., Wang D., Rangwala F., Keam B. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018; 36(1): 7-13. https://doi.org/10.1200/JCO.2017.73.6785.
  • Long G.V., Flaherty K.T., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T., Hauschild A., Chiarion-Sileni V., Lebbe C., Mandala M., MillwardM., Arance A., Bondarenko I., Haanen J.B.A.G., Hansson J., Utikal J., Ferraresi V., Mohr P., Probachai V., Schadendorf D., Nathan P., Robert C., Ribas A., Davies M.A., Lane S.R., Legos J.J., Mookerjee B., Grob J.J. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017; 28(7): 1631-39. https://doi.org/10.1093/annonc/mdx176. Erratum in: Ann Oncol. 2019; 30(11): 1848. https://doi.org/10.1093/annonc/mdz221.
  • Subbiah V., Kreitman R.J., Wainberg Z.A., Cho J.Y., Schellens J.H.M., Soria J.C., Wen P.Y., Zielinski C.C., Cabanillas M.E., Boran A., Ilankumaran P., Burgess P., Romero Salas T., Keam B. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022; 33(4): 406-15. https://doi.org/10.1016/j.annonc.2021.12.014.
  • Wang J.R., Zafereo M.E., Dadu R., Ferrarotto R., Busaidy N.L., Lu C., Ahmed S., Gule-Monroe M.K., Williams M.D., Sturgis E.M., Goepfert R.P., Gross N.D., Lai S.Y., Gunn G.B., Phan J., Rosenthal D.I., Fuller C.D., Morrison W.H., Iyer P., Cabanillas M.E. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019; 29(8): 1036-43. https://doi.org/10.1089/thy.2019.0133.
  • FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation [Internet]. Food and Drug Administration (FDA). 2022. [cited 2024 Jul 10]. URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid.
  • Pembrolizumab (Keytruda) 5-10-2017 [Internet]. Food and Drug Administration (FDA). 2017. [cited 2024 Jul 10]. URL: https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda-5-10-2017.
  • Capdevila J., WirthL.J., Ernst T., Ponce Aix S., Lin C.C., Ramlau R., Butler MO., Delord J.P., Gelderblom H., Ascierto P.A., Fasolo A., Führer D., Hütter-Krönke M.L., Forde PM., Wrona A., Santoro A., Sadow P.M., Szpakowski S., Wu H., Bostel G., Faris J., Cameron S., Varga A., Taylor M. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020; 38(23): 2620-27. https://doi.org/10.1200/JCO.19.02727.
  • Lorch J.H., Barletta J., Nehs M., Uppaluri R., Alexander E.K., Haddad R.I., Hanna G.J., Margalit D.N., Tishler R.B., Schoenfeld J., Goguen LA., Jabiev A., Sorensen M.J., Ahmadi S., Marqusee E., Kim M.I., Stanizzi D., Harris E., Kacew A., Barbie D.A. A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC). J Clin Oncol. 2020; 38(s15): 6513. https://doi.org/10.1200/JCO.2020.38.15_suppl.6513.
  • Dierks C., Seufert J., Aumann K., Ruf J., Klein C., Kiefer S., Rassner M., Boerries M., Zielke A., la Rosee P., Meyer P.T., Kroiss M., Weifienberger C., Schumacher T., MetzgerP., WeissH., SmaxwilC., LaubnerK., Duyster J., vonBubnoffN, Miething C., Thomusch O. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid. 2021; 31(7): 1076-85. https://doi.org/10.1089/thy.2020.0322.
  • Dierks C., Ruf J., Seufert J., Kreissl M., Klein C., Spitzweg C., Kroiss M., Thomusch O., Lorenz K., Zielke A., Miething C. 1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. Ann Oncol. 2022; 33(s7).
  • CabanillasM.E., FerrarottoR., GardenA.S., AhmedS., BusaidyN.L., Dadu R., Williams M.D., Skinner H., Gunn G.B., Grosu H., Iyer P., Hofmann M.C., Zafereo M. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid. 2018; 28(7): 945-51. https://doi.org/10.1089/thy.2018.0060.
  • Hamidi S., Iyer P.C., Dadu R., Gule-Monroe M.K., Maniakas A., Zafereo M.E., Wang J.R., Busaidy N.L., Cabanillas M.E. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024; 34(3): 336-46. https://doi.org/10.1089/thy.2023.0573.
  • Cohen E.E., Rosen L.S., Vokes E.E., Kies M.S., Forastiere A.A., Worden F.P., Kane M.A., Sherman E., Kim S., Bycott P., Tortorici M., Shalinsky D.R., Liau K.F., Cohen R.B. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008; 26(29): 4708-13. https://doi.org/10.1200/JCO.2007.15.9566.
  • Gupta-Abramson V., Troxel A.B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., Mandel S.J., Flaherty K.T., Loevner L.A., O'Dwyer P.J., Brose M.S. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008; 26(29): 4714-19. https://doi.org/10.1200/JCO.2008.16.3279.
  • Savvides P., Nagaiah G., Lavertu P., Fu P., Wright J.J., Chapman R., Wasman J., Dowlati A., Remick S.C. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013; 23(5): 600-4. https://doi.org/10.1089/thy.2012.0103.
  • Bible K.C., Suman V.J., Menefee M.E., Smallridge R.C., Molina J.R., Maples W.J., Karlin N.J., Traynor A.M., Kumar P., Goh B.C., Lim W.T., Bossou A.R., Isham C.R., Webster K.P., Kukla A.K., Bieber C., Burton J.K., Harris P., Erlichman C.; Mayo Phase 2 Consortium; Mayo Clinic Endocrine Malignances Disease Oriented Group. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012; 97(9): 3179-84. https://doi.org/10.1210/jc.2012-1520.
  • Takahashi S., Kiyota N., Yamazaki T., Chayahara N., Nakano K., Inagaki L., Toda K., Enokida T., Minami H., Imamura Y., Fukuda N., Sasaki T., Suzuki T., Ikezawa H., Dutcus C.E., Tahara M. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 2019; 15(7): 717-26. https://doi.org/10.2217/fon-2018-0557.
  • Sugitani I., Onoda N., Ito K.I., Suzuki S. Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan. J Nippon Med Sch. 2018; 85(1): 18-27. https://doi.org/10.1272/jnms.2018_85-3.
  • Wirth L.J., Brose M.S., Sherman E.J., Licitra L., Schlumberger M., Sherman S.I., Bible K.C., Robinson B., Rodien P., Godbert Y., De La Fouchardiere C., Newbold K., Nutting C., Mi sir S., Xie R., A lm onte A., Ye W., Cabanillas M.E. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. J Clin Oncol. 2021; 39(21): 2359-66. https://doi.org/10.1200/JCO.20.03093.
  • Wagle N., Grabiner B.C., Van Allen E.M., Amin-Mansour A., Taylor-Weiner A., Rosenberg M., Gray N., Barletta J.A., Guo Y., Swanson S.J., Ruan D.T., Hanna G.J., Haddad R.I., Getz G., Kwiatkowski D.J., Carter S.L., Sabatini D.M., Janne P.A., Garraway L.A., Lorch J.H. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014; 371(15): 1426-33. https://doi.org/10.1056/NEJMoa1403352.
  • Schneider T.C., de Wit D., Links T.P., van Erp N.P., van der Hoeven J.J., Gelderblom H., Roozen I.C., Bos M., Corver W.E., van Wezel T., Smit J.W., Morreau H., Guchelaar H.J., Kapiteijn E. Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial. J Clin Endocrinol Metab. 2017; 102(2): 698-707. https://doi.org/10.1210/jc.2016-2525. Erratum in: J Clin Endocrinol Metab. 2017; 102(6): 2125. https://doi.org/10.1210/jc.2017-00661.
  • Pennell N.A., Daniels G.H., Haddad R.I., Ross D.S., Evans T., Wirth L.J., Fidias P.H., Temel J.S., Gurubhagavatula S., Heist R.S., Clark J.R., Lynch T.J. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008; 18(3): 317-23. https://doi.org/10.1089/thy.2007.0120.
  • Godbert Y., Henriques de Figueiredo B., Bonichon F., Chibon F., Hostein I., Perot G., Dupin C., Daubech A., Belleannee G., Gros A., Italiano A., Soubeyran I. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma. J Clin Oncol. 2015; 33(20). https://doi.org/10.1200/JCO.2013.49.6596.
  • Leroy L., Bonhomme B., Le Moulec S., Soubeyran I., Italiano A., Godbert Y. Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib. Thyroid. 2020; 30(2): 343-44. https://doi.org/10.1089/thy.2019.0202.
  • Sheth S., Lu R., Zhu H., Ugwu E., Qin F., Morton H., Steffen M., Miles C., Winters E., Lai S., Kang H., Khanna V., Khan S. Phase II trial of Abemaciclib in Unresectable or Metastatic Anaplastic Thyroid Cancer. Int J Rad Oncol Biol Phys. 2024; 118(5). https://doi.org/10.1016/j.ijrobp.2024.01.184.
  • Maniakas A., Dadu R., Busaidy N.L., Wang J.R., Ferrarotto R., Lu C., Williams M.D., Gunn G.B., Hofmann M.C., Cote G., Sperling J., Gross N.D., Sturgis E.M., Goepfert R.P., Lai S.Y., Cabanillas M.E., Zafereo M. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020; 6(9): 1397-404. https://doi.org/10.1001/jamaoncol.2020.3362.
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp